Pacira BioSciences Reports Third-Quarter 2026 Financial Results
Pacira BioSciences announced its financial results for the third quarter of 2026, reporting $176.65 million in revenue and $0.70 in diluted earnings per share.
Stocks · News reference
Top 3 Health Care Stocks That May Fall Off A Cliff In October
Option Care Health, Pacira Biosciences and HealthStream show overbought RSI levels above 83, warning momentum-focused investors.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
McKesson and Clayton, Dubilier & Rice Secure Financing for Option Care Health Acquisition
McKesson Corporation and private equity firm Clayton, Dubilier & Rice have engaged Wall Street banks to arrange $3.1 billion in financing for their acquisition of Option Care Health.
8-K filing — Pacira BioSciences, Inc. (PCRX)
Filed: 2026-11-05 AccNo: 0001628280-26-071129 Size: 152 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Canaccord Genuity Maintains HealthStream at Hold, Raises Price Target to $32
Canaccord Genuity has maintained its 'Hold' rating on HealthStream, Inc. while increasing the price target from $29 to $32.
Craig-Hallum Downgrades HealthStream to Hold
Craig-Hallum downgraded HealthStream from buy to hold, citing valuation concerns despite positive quarterly results.
Option Care Health Reports Third Quarter 2026 Financial Results
Option Care Health announced its financial results for the third quarter ended September 30, 2026, reporting growth in revenue and net income while noting the withdrawal of financial guidance due to a pending acquisition.